deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT05827146

Study of Hepalatide in Chronic Hepatitis D(CHD) Patients

Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D

Sponsor: Shanghai HEP Pharmaceutical Co., Ltd.

Conditions Chronic Hepatitis D Infection
Interventions Hepalatide Hepalatide Placebo
Updated 6 times since 2023 Last updated: Apr 22, 2024 Started: Oct 7, 2023 Primary completion: Jan 30, 2024 Completion: Feb 1, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Hepatitis D Infection and is currently completed. Shanghai HEP Pharmaceutical Co., Ltd. leads this study, which shows 6 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~May 2023 – ~Jan 2024 · 8 months · monthly snapshotNot Yet Recruiting~Jan 2024 – ~May 2024 · 4 months · monthly snapshotRecruiting~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Jan 2024 — May 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

  1. May 2023 — Jan 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai HEP Pharmaceutical Co., Ltd.
Data source: Shanghai HEP Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations